0001104659-22-005555.txt : 20220119 0001104659-22-005555.hdr.sgml : 20220119 20220119181922 ACCESSION NUMBER: 0001104659-22-005555 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220114 FILED AS OF DATE: 20220119 DATE AS OF CHANGE: 20220119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mandelia Ashish CENTRAL INDEX KEY: 0001782805 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38129 FILM NUMBER: 22540005 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mersana Therapeutics, Inc. CENTRAL INDEX KEY: 0001442836 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-498-0020 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: MERSANA THERAPEUTICS INC DATE OF NAME CHANGE: 20080813 4 1 tm223926-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-01-14 0 0001442836 Mersana Therapeutics, Inc. MRSN 0001782805 Mandelia Ashish C/O MERSANA THERAPEUTICS, INC. 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 0 1 0 0 VP, Controller Common Stock 2022-01-14 4 M 0 5353 A 5353 D Common Stock 2022-01-18 4 S 0 1982 5.92 D 3371 D Restricted Stock Units 2022-01-14 4 M 0 833 0 D Common Stock 833 1666 D Restricted Stock Units 2022-01-14 4 M 0 4520 0 D Common Stock 4520 13557 D Stock Option (right to buy) 6.28 2022-01-14 4 A 0 28700 0 A 2032-01-13 Common Stock 28700 28700 D Restricted Stock Units 2022-01-14 4 A 0 19133 0 A Common Stock 19133 19133 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon vesting. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II. These sales were mandated by the Issuer's election under its equity incentive plans to require the reporting person to sell a number of shares of common stock needed to satisfy his tax withholding obligations and does not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.83 to $5.92, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. 50% of the total number of RSUs vested as of January 14, 2022, and thereafter shall vest in equal annual installments over the next two years. 25% of the total number of RSUs vested on January 14, 2022, and thereafter shall vest in equal annual installments over the next three years. The option vests in equal quarterly installments over the first four years after the vesting commencement date, January 14, 2022. The restricted stock units vest in equal annual installments over the first four years after the vesting commencement date, January 14, 2022. /s/ Brian DeSchuytner, as Attorney-in-Fact 2022-01-19